Home Cart Sign in  
Chemical Structure| 1899921-05-1 Chemical Structure| 1899921-05-1

Structure of Almonertinib
CAS No.: 1899921-05-1

Chemical Structure| 1899921-05-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

HS-10296 is the third-generation EGFR TKIs which exhibited inhibitory effect on both EGFR-activating mutations and T790M-resistant mutation.

Synonyms: HS-10296; Ameile; Aumolertinib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Almonertinib

CAS No. :1899921-05-1
Formula : C30H35N7O2
M.W : 525.64
SMILES Code : C=CC(NC1=CC(NC2=NC=CC(C3=CN(C4CC4)C5=C3C=CC=C5)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Synonyms :
HS-10296; Ameile; Aumolertinib
MDL No. :MFCD32173681

Safety of Almonertinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Almonertinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • mutant EGFR

In Vitro:

Cell Line
Concentration Treated Time Description References
LU0387 cells 312 nM 7 days Evaluate the inhibitory effect of Almonertinib on the proliferation of LU0387 cells with EGFR NPH mutation PMC10326255
Human NSCLC cell lines HCC827 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1 μM 72 h To determine the IC50 of Almonertinib on HCC827 cells, results showed significant inhibitory effects in EGFR-del19 mutant cells. PMC9063085
Human NSCLC cell lines H1975 0.01, 0.1, 1, 10, 20, 50, 100 μM 72 h To determine the IC50 of Almonertinib on H1975 cells, results showed significant inhibitory effects in EGFR L858R/T790M mutant cells. PMC9063085
Human NSCLC cell lines A549 1, 2, 5, 10, 20, 50, 100 μM 72 h To determine the IC50 of Almonertinib on A549 cells, results showed weak inhibitory effects in EGFR wild-type cells. PMC9063085
HCC827/AR cells 8 μM 24 h To evaluate the effects of Almonertinib combined with Baicalein on cell proliferation and apoptosis. Results showed that the combination significantly inhibited cell proliferation and induced apoptosis. PMC11322074
H1975/AR cells 8 μM 24 h To evaluate the effects of Almonertinib combined with Baicalein on cell proliferation and apoptosis. Results showed that the combination significantly inhibited cell proliferation and induced apoptosis. PMC11322074
BCRP-MDCK monolayer cells 1, 10, 20 μM 4 h To study the transport characteristics of Almonertinib in BCRP-MDCK cells, results showed an efflux ratio of 4.62 at 1 μM concentration PMC8497791
ABCB1-MDCK monolayer cells 1, 10, 20 μM 4 h To study the transport characteristics of Almonertinib in ABCB1-MDCK cells, results showed an efflux ratio of 5.2 at 1 μM concentration PMC8497791

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Ba/F3 EGFR ASV and L861Q allografts model Oral 20 and 40 mg/kg Once daily for 13 days Evaluate the inhibitory effect of Almonertinib on tumor growth with EGFR ASV and L861Q mutations PMC10326255
Balb/c nude mice H1975 and HCC827 xenograft model Oral 20 mg/kg Once daily, multiple cycles (4 days per cycle) To evaluate the anti-tumor effect of Almonertinib in H1975 and HCC827 xenograft models, results showed that P-A sequence (pemetrexed followed by Almonertinib) exhibited significant synergistic anti-tumor effects. PMC9063085
BALB/c nude mice Subcutaneous HCC827/AR cell xenograft model 15 mg/kg 24 days To evaluate the inhibitory effects of Almonertinib combined with Baicalein on tumor growth. Results showed that the combination significantly inhibited tumor growth. PMC11322074
BALB/c nude mice PC9-LUC brain and spinal cord metastasis models Oral 5, 10, 25 mg/kg Once daily for 60 days To evaluate the anti-tumor efficacy of Almonertinib in brain and spinal cord metastasis models, results showed that 25 mg/kg Almonertinib significantly inhibited tumor growth and prolonged survival time PMC8497791
Rats Healthy SD rats Oral 15 mg/kg For nine consecutive days To evaluate the pharmacokinetic interactions between almonertinib and rivaroxaban or apixaban. Results showed that almonertinib significantly increased the plasma concentration and AUC of rivaroxaban and apixaban, and decreased their clearance. PMC10582335

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04785742 Safety of Almonertinib PHASE2 UNKNOWN 2023-12-31 Sun Yat-sen University Cancer ... More >>Center, Guangzhou, Guang Dong, China Less <<
NCT04952168 NSCLC, Stage III PHASE2 UNKNOWN 2023-06-02 Tongji Hospital of Tongji Medi... More >>cal College of Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China Less <<
NCT04922138 Lung Cancer PHASE2 RECRUITING 2025-10-15 Shanghai Chest Hospital, Shang... More >>hai, Shanghai, 200000, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, 200000, China Less <<
NCT04636593 Non Small Cell Lung Cancer|Sta... More >>ge III NSCLC|EGFR Activating Mutation Less << PHASE2 UNKNOWN 2022-12-31 Hangzhou Cancer hospital, Hang... More >>zhou, Zhejiang, 310002, China Less <<
NCT06463171 Lung Cancer Non-small Cell Sta... More >>ge IV Less << PHASE2 NOT_YET_RECRUITING 2025-06-26 Zhongshan hospital, Shanghai, ... More >>200032, China|The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China Less <<
NCT04354961 Pulmonary Adenosquamous Carcin... More >>oma Less << PHASE2 RECRUITING 2025-06-30 Beijing Cancer Hospital, Beiji... More >>ng, China|Beijing Chest Hospital, Capital Medical University, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China|Hunan Cancer Hospital, Changsha, China|The Second Xiangya Hospital of Central South University, Changsha, China|Xinqiao Hospital, Army Medical University, Chongqing, China|Fujian Cancer Hospital, Fuzhou, China|Fujian Provincial Hospital, Fuzhou, China|Sir Run Run Shaw Hospital, Hangzhou, China|The second Affiliated Hospital of Kunming Medical University, Kunming, China|The second Affiliated Hospital of Nanchang University, Nanchang, China|Jiangsu Province Hospital, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, China|Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China|Air Force Medical University of PLA (the Fourth Military Medical University), Xi'an, China|Henan Cancer Hospital, Zhengzhou, China|Henan Provincial People's Hospital, Zhengzhou, China Less <<
NCT06227897 Lung Cancer PHASE2 WITHDRAWN 2029-04-01 Sun Yat-sen University Cancer ... More >>Center, Guangzhou, Guangdong, 510060, China Less <<
NCT04841811 Lung Cancer PHASE3 RECRUITING 2026-12-31 Guangdong Lung cancer institut... More >>e, Guangzhou, Guangdong, 510080, China Less <<
NCT05662813 Non-small Cell Lung Cancer PHASE2 RECRUITING 2025-06-30 West China Hospital,Sichuan Un... More >>iversity, Chendu, Sichuan, China Less <<
NCT05994339 Lung Cancer Stage III PHASE2|PHASE3 NOT_YET_RECRUITING 2025-12-08 -
NCT04882345 Lung Cancer|EGFR Gene Mutation PHASE2 UNKNOWN 2024-01-15 -
NCT05826483 Malignant Tumor of Lung|Poor P... More >>erformance Status Less << PHASE1 RECRUITING 2024-12-30 Zhou Chengzhi, Guangzhou, Guan... More >>gdong, 510120, China Less <<
NCT05946460 Lung Cancer PHASE2 RECRUITING 2025-07-10 The First Affiliated Hospital ... More >>of Guangzhou Medical University, Guangzhou, Guangdong, 510000, China Less <<
NCT02981108 Nonsmall Cell Lung Cancer PHASE1|PHASE2 UNKNOWN 2023-03-31 Pacific Cancer Medical Center,... More >> Inc., Anaheim, California, 92801, United States|Beverly Hills Cancer Center, Beverly Hills, California, 90211, United States|University of California San Diego Medical Center Moores Cancer Center, San Diego, California, 92093, United States|University of Colorado-1775 Aurora Court, Aurora, Colorado, 80045, United States|Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, 33442, United States|University Cancer & Blood Center, LLC, Athens, Georgia, 30607, United States|Baptist Healthcare Systems Inc. Baptist Health Floyd, New Albany, Indiana, 47150, United States|Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, 03755, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, 77550, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, 98405, United States Less <<
NCT04643847 EGFR Positive Non-small Cell L... More >>ung Cancer|Brain Metastases Less << PHASE2 UNKNOWN 2023-11-30 Hangzhou Cancer Hospital, Hang... More >>zhou, Zhejiang, 310002, China Less <<
NCT04553887 Non Small Cell Lung Cancer PHASE2 UNKNOWN 2023-05-01 Tianjin Medical University Can... More >>cer Institute and Hospital, Tianjin, Tianjin, China Less <<
NCT04808752 Lung Cancer PHASE2 ACTIVE_NOT_RECRUITING 2024-07-15 Cancer Hospital Affiliated to ... More >>University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310000, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.51mL

1.90mL

0.95mL

19.02mL

3.80mL

1.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories